Hua Xin Liao

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins
    Hua Xin Liao
    Duke Human Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
    J Virol 78:5270-8. 2004
  2. pmc Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design
    Mattia Bonsignori
    Duke Human Vaccine Institute, Durham, North Carolina, USA
    J Virol 86:4688-92. 2012
  3. pmc Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41
    S Moses Dennison
    Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America
    PLoS ONE 6:e27824. 2011
  4. pmc Generation of mucosal anti-human immunodeficiency virus type 1 T-cell responses by recombinant Mycobacterium smegmatis
    Jae Sung Yu
    Human Vaccine Institute and Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Vaccine Immunol 13:1204-11. 2006
  5. pmc Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization
    Curtis P Bradney
    Department of Medicine, Human Vaccine Institute, Center for AIDS Research, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Virol 76:517-24. 2002
  6. pmc Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen
    Eric A Weaver
    Duke Human Vaccine Institute, Duke University Medical Center, 112 RPIII, Research Drive, Box 3347, DUMC, Durham, NC 27710, USA
    J Virol 80:6745-56. 2006
  7. pmc Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Immunity 38:176-86. 2013
  8. pmc HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages
    M Anthony Moody
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA
    J Virol 86:7496-507. 2012
  9. pmc Recombinant Mycobacterium bovis bacillus Calmette-Guerin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites
    Jae Sung Yu
    Human Vaccine Institute and Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Vaccine Immunol 14:886-93. 2007
  10. pmc Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein
    Feng Gao
    Department of Medicine, Duke University Medical Center, 112 Research Park III, Research Dr, Box 3347, Durham, NC 27710, USA
    J Virol 79:1154-63. 2005

Detail Information

Publications66

  1. pmc Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins
    Hua Xin Liao
    Duke Human Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
    J Virol 78:5270-8. 2004
    ....
  2. pmc Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design
    Mattia Bonsignori
    Duke Human Vaccine Institute, Durham, North Carolina, USA
    J Virol 86:4688-92. 2012
    ..These data provide proof of concept for an HIV-1 vaccine that aims to elicit bnAbs of multiple specificities...
  3. pmc Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41
    S Moses Dennison
    Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America
    PLoS ONE 6:e27824. 2011
    ..Nonetheless, the Env-liposome prime-boost immunization strategy induced antibodies that recognized a gp41 fusion intermediate protein and was successful in focusing the antibody response to the desired epitope...
  4. pmc Generation of mucosal anti-human immunodeficiency virus type 1 T-cell responses by recombinant Mycobacterium smegmatis
    Jae Sung Yu
    Human Vaccine Institute and Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Vaccine Immunol 13:1204-11. 2006
    ..However, immunization with recombinant M. smegmatis expressing HIV-1 Env was able to prime for an HIV-1 Env protein boost for the induction of anti-HIV-1 antibody responses...
  5. pmc Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization
    Curtis P Bradney
    Department of Medicine, Human Vaccine Institute, Center for AIDS Research, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Virol 76:517-24. 2002
    ..These results indicate that the proinflammatory cytokines IL-1alpha, IL-12, and IL-18 can replace CT as a mucosal adjuvant for antibody induction and are important candidates for use as mucosal adjuvants with HIV and other vaccines...
  6. pmc Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen
    Eric A Weaver
    Duke Human Vaccine Institute, Duke University Medical Center, 112 RPIII, Research Drive, Box 3347, DUMC, Durham, NC 27710, USA
    J Virol 80:6745-56. 2006
    ....
  7. pmc Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Immunity 38:176-86. 2013
    ..Variation may signal sites of HIV-1 envelope vulnerability, providing vaccine designers with new options...
  8. pmc HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages
    M Anthony Moody
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA
    J Virol 86:7496-507. 2012
    ..Improved vaccination strategies will be needed to drive persistent stimulation of antibody clonal lineages to induce affinity maturation that results in highly mutated HIV-1 Env-reactive antibodies...
  9. pmc Recombinant Mycobacterium bovis bacillus Calmette-Guerin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites
    Jae Sung Yu
    Human Vaccine Institute and Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Vaccine Immunol 14:886-93. 2007
    ..However, rBCG could prime for a protein boost by HIV-1 envelope protein. Thus, rBCG can serve as a vector for induction of anti-HIV-1 consensus Env cellular responses at mucosal sites...
  10. pmc Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein
    Feng Gao
    Department of Medicine, Duke University Medical Center, 112 Research Park III, Research Dr, Box 3347, Durham, NC 27710, USA
    J Virol 79:1154-63. 2005
    ..Thus, the computer-generated "consensus" env genes are capable of expressing envelope glycoproteins that retain the structural, functional, and immunogenic properties of wild-type HIV-1 envelopes...
  11. pmc Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion
    S Munir Alam
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA
    J Virol 87:1554-68. 2013
    ..These results demonstrate that deletion of N-terminal residues in the RV144 A244 gp120 immunogen improves both envelope antigenicity and immunogenicity...
  12. pmc Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection
    S Munir Alam
    Human Vaccine Institute, Box 3258, Duke University Medical Center, MSRBII Bldg, Room 4042, Durham, NC 27710, USA
    J Virol 82:115-25. 2008
    ....
  13. pmc A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
    Virology 353:268-82. 2006
    ..Our study also shows the feasibility of iterative improvements in Env immunogenicity by rational design of centralized genes...
  14. ncbi request reprint Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates
    Barton F Haynes
    Department of Medicine and Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
    Virology 345:44-55. 2006
    ....
  15. pmc Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG
    Georgia D Tomaras
    Duke Human Vaccine Institute, and Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 110:9019-24. 2013
    ..We show that monomeric Env-specific IgA, as part of postvaccination polyclonal antibody response, may modulate vaccine-induced immunity by diminishing ADCC effector function...
  16. pmc Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees
    Pinghuang Liu
    Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA
    J Virol 87:7828-36. 2013
    ..Although capture of infectious HIV-1 correlated with other humoral immune responses, the extent of variation between these humoral responses and virion capture indicates that virion capture antibodies occupy unique immunological space. ..
  17. pmc Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting
    Lynn Morris
    Duke Human Vaccine Institute and Departments of Medicine, Surgery and Immunology, Duke University School of Medicine, Durham, North Carolina, United States of America
    PLoS ONE 6:e23532. 2011
    ..These data indicate that there are multiple immunogenic targets in the C-terminus of the MPER of HIV-1 gp41 envelope and suggests that gp41 neutralizing epitopes may interact with a restricted set of naive B cells during HIV-1 infection...
  18. pmc Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines
    M Anthony Moody
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Exp Med 207:763-76. 2010
    ..The release of these beta-chemokines explains both the specificity for R5 HIV-1 and the activity of these mAbs in PBMC cultures containing both primary lymphocytes and monocytes...
  19. pmc Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA
    J Virol 87:4185-201. 2013
    ....
  20. pmc Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies
    Guang Yang
    Department of Immunology, Duke University, Durham, NC 27705, USA
    J Exp Med 210:241-56. 2013
    ..Identification of structural motifs shared by vertebrates and HIV-1 provides direct evidence that immunological tolerance can impair humoral responses to HIV-1...
  21. ncbi request reprint Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies
    Barton F Haynes
    Duke University School of Medicine, Durham, NC 27710, USA
    Science 308:1906-8. 2005
    ..These results may have important implications for generating effective neutralizing antibody responses by using HIV-1 vaccines...
  22. pmc Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation
    S Munir Alam
    Human Vaccine Institute, Duke University Medical Center, 2 Genome Court, P O Box 103020, Durham, NC 27710, USA
    J Virol 85:11725-31. 2011
    ..Thus, these data demonstrate a genetically determined trait that may affect host responses to HIV-1 envelope epitopes recognized by broadly neutralizing antibodies and has implications for unmutated ancestor-based immunogen design...
  23. ncbi request reprint Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques
    M Anthony Moody
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA
    J Virol 88:3329-39. 2014
    ....
  24. ncbi request reprint Expression of the CD7 ligand K-12 in human thymic epithelial cells: regulation by IFN-gamma
    Gordon K Lam
    Department of Medicine, Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA
    J Clin Immunol 25:41-9. 2005
    ..These data suggest a role for thymic microenvironment-produced K12 in regulation of thymocyte signaling and cytokine release, particularly in the setting of thymus pathology where IFN-gamma is upregulated such as myasthenia gravis...
  25. pmc Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
    J Exp Med 208:2237-49. 2011
    ..These data suggest that the majority of gp41-binding antibodies produced after acute HIV-1 infection are cross-reactive responses generated by stimulating memory B cells that have previously been activated by non-HIV-1 antigens...
  26. pmc Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens
    S Moses Dennison
    Duke Human Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710, USA
    J Virol 85:1340-7. 2011
    ..These results demonstrate that lipid-reactive gp41 cluster II antibodies are nonneutralizing due to their inability to bind to the relevant neutralizing epitopes on gp41...
  27. pmc Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses
    Laurent Verkoczy
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 191:2538-50. 2013
    ....
  28. ncbi request reprint An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120
    S Munir Alam
    Department of Medicine, Duke Center for AIDS Research, Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina 27707, USA
    AIDS Res Hum Retroviruses 20:836-45. 2004
    ..This may prove to be an important consideration when designing an HIV vaccine that utilizes constrained HIV Env proteins...
  29. pmc Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
    Hua Xin Liao
    Duke University Human Vaccine Institute, Departments of Medicine and Immunology, Duke University School of Medicine, Durham, North Carolina 27710, USA
    Nature 496:469-76. 2013
    ..These data determine the viral and antibody evolution leading to induction of a lineage of HIV-1 broadly neutralizing antibodies, and provide insights into strategies to elicit similar antibodies by vaccination...
  30. pmc Role of HIV membrane in neutralization by two broadly neutralizing antibodies
    S Munir Alam
    Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 106:20234-9. 2009
    ..These results bear directly on strategies for rational design of HIV-1 envelope immunogens...
  31. pmc B cell responses to HIV-1 infection and vaccination: pathways to preventing infection
    Barton F Haynes
    Duke Human Vaccine Institute and the Duke Center for AIDS Research, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
    Trends Mol Med 17:108-16. 2011
    ....
  32. ncbi request reprint Capacity for Infectious HIV-1 Virion Capture Differs by Envelope Antibody Specificity
    Pinghuang Liu
    Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA
    J Virol 88:5165-70. 2014
    ..Infectious virion capture was additive with a mixture of antibodies, providing proof of concept for vaccine-induced antibodies that together have improved capacity to recognize infectious virions. ..
  33. ncbi request reprint Detection of Ebola virus envelope using monoclonal and polyclonal antibodies in ELISA, surface plasmon resonance and a quartz crystal microbalance immunosensor
    Jae Sung Yu
    Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, United States
    J Virol Methods 137:219-28. 2006
    ..Thus, polyclonal and monoclonal antibodies can be used in combination to identify and differentiate both human and non-human primate EBOV GPs...
  34. pmc HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design
    Mattia Bonsignori
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Trends Microbiol 20:532-9. 2012
    ..Strategies are being developed for the analysis of infection and vaccine candidate-induced antibodies, their gene usage, and their maturation pathways such that this information can be used to attempt to guide rational vaccine design...
  35. pmc Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins
    Feng Gao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Virology 394:91-8. 2009
    ..Nonetheless, such mAbs represent valuable reagents to study the biochemistry and structural biology of Env protein oligomers...
  36. ncbi request reprint HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities
    Justin Pollara
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    J Virol 88:7715-26. 2014
    ....
  37. pmc Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk
    Genevieve G A Fouda
    Duke Human Vaccine Institute, Durham, North Carolina, USA
    J Virol 87:6986-99. 2013
    ..This study shows that systemic MVA prime followed by either intranasal or systemic protein boosts can elicit strong humoral responses in breast milk and may be a useful strategy to interrupt postnatal HIV-1 transmission...
  38. pmc Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family
    Mattia Bonsignori
    Duke University Medical Center, Durham, North Carolina, USA
    J Virol 86:11521-32. 2012
    ..The polyclonality and low mutation frequency of these VH1 antibodies reveal fundamental differences in the regulation and maturation of these ADCC-mediating responses compared to VH1 bNAbs...
  39. pmc Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors
    Mattia Bonsignori
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 85:9998-10009. 2011
    ..Thus, E.A244, B.9021, and AE.CM243 Envs are three potential immunogen candidates for studies aimed at defining strategies to induce V2/V3 conformational epitope-specific antibodies...
  40. pmc Anti-Ebola MAb 17A3 reacts with bovine and human alpha-2-macroglobulin proteins
    Jae Sung Yu
    Departments of Medicine, Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Virol Methods 168:248-50. 2010
    ..Thus, while MAbs 15H10 and 6D11 are indeed EBOV GP specific, MAb 17A3 is an alpha-2-macroglobulin MAb...
  41. pmc Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors
    S Munir Alam
    Duke Human Vaccine Institute and Departments of Medicine, Pathology, and Immunology, Duke University Medical Center, Durham, NC 27710
    Proc Natl Acad Sci U S A 110:18214-9. 2013
    ....
  42. pmc Tenascin-C is an innate broad-spectrum, HIV-1-neutralizing protein in breast milk
    Genevieve G Fouda
    Human Vaccine Institute, Department of Cell Biology, Institute for Genome Sciences and Policy, and Department of Pediatrics, Duke University Medical Center, Durham, NC 27710
    Proc Natl Acad Sci U S A 110:18220-5. 2013
    ....
  43. pmc Immune-correlates analysis of an HIV-1 vaccine efficacy trial
    Barton F Haynes
    Duke University Human Vaccine Institute and the Center for HIV AIDS Vaccine Immunology, Duke University School of Medicine, Durham, NC 27710, USA
    N Engl J Med 366:1275-86. 2012
    ..In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case-control analysis to identify antibody and cellular immune correlates of infection risk...
  44. doi request reprint Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region
    Nathan I Nicely
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA
    Nat Struct Mol Biol 17:1492-4. 2010
    ..We show that unlike 2F5, 13H11 binds to a well-defined helical MPER structure that is consistent with the structure of gp41 in a post-fusion six-helix bundle conformation...
  45. pmc Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance
    Laurent Verkoczy
    Duke Human Vaccine Institute and Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 107:181-6. 2010
    ..These features are consistent with elimination of 2F5 HC autoreactivity by additional negative selection mechanism(s) in the periphery...
  46. pmc Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies
    Ben Jiang Ma
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America
    PLoS Pathog 7:e1002200. 2011
    ....
  47. pmc Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production
    Anthony R Geonnotti
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    AIDS Res Hum Retroviruses 26:279-91. 2010
    ..The results also highlight the need to use endotoxin-free specimens to avoid artifacts when assessing HIV-1-specific neutralizing antibodies in PBMC-based assays...
  48. pmc epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals
    Haili Tang
    Department of Surgery, Box 2926, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 85:9286-99. 2011
    ..We conclude that a region just below the base of the V3 loop, near the coreceptor binding domain of gp120, can be a target for autologous neutralization...
  49. pmc Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions
    S Moses Dennison
    Human Vaccine Institute, Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710, USA
    J Virol 83:10211-23. 2009
    ..These data have important implications for the design and use of peptide-liposome conjugates as immunogens for the induction of MPER-neutralizing antibodies...
  50. pmc Gender differences in human immunodeficiency virus type 1-specific CD8 responses in the reproductive tract and colon following nasal peptide priming and modified vaccinia virus Ankara boosting
    James W Peacock
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 78:13163-72. 2004
    ..Understanding the cellular and molecular basis of gender-determined immune responses will be important for optimizing induction of anti-HIV-1 mucosal immune responses in both males and females...
  51. ncbi request reprint Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination
    Nicole L Yates
    Duke Human Vaccine Institute, Durham, NC 27710, USA
    Sci Transl Med 6:228ra39. 2014
    ..These data suggest that specific vaccine-induced HIV-1 IgG3 should be tested in future studies of immune correlates in HIV-1 vaccine efficacy trials. ..
  52. pmc Enhanced outgrowth of EBV-transformed chronic lymphocytic leukemia B cells mediated by coculture with macrophage feeder cells
    Kwan Ki Hwang
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Blood 119:e35-44. 2012
    ..Thus, we have established enhanced methods of B-CLL culture that will enable broader interrogation of B-CLL cells at the genetic and protein levels...
  53. pmc Murine CD7 shares antigenic cross-reactivity with HSP-60
    Brandon A Howard
    Departments of Medicine, Duke University Medical Center, Duke Human Vaccine Institute, Durham, North Carolina, USA
    Hybridoma (Larchmt) 27:81-9. 2008
    ..These data demonstrated molecular mimicry of mCD7 with HSP-60, and leave open the question of surface expression of mCD7...
  54. pmc Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia
    Georgia D Tomaras
    Duke Human Vaccine Institute, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 82:12449-63. 2008
    ..These results demonstrate that the first IgM and IgG antibodies induced by transmitted HIV-1 are capable of binding virions but have little impact on acute-phase viremia at the timing and magnitude that they occur in natural infection...
  55. pmc A polymorphism in the HCP5 gene associated with HLA-B*5701 does not restrict HIV-1 in vitro
    Woohyun Yoon
    Center for Human Genome Variation, Duke Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, USA
    AIDS 24:155-7. 2010
    ....
  56. ncbi request reprint Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity
    Feng Gao
    The Duke Human Vaccine Institute, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
    Expert Rev Vaccines 3:S161-8. 2004
    ..It is biologically functional and preserves antigenicity similar to contemporary Env proteins. Most importantly, the group M consensus Env immunogen can elicit both T- and B-cell responses to wild-type HIV-1 isolates...
  57. pmc Comparison of multiple vaccine vectors in a single heterologous prime-boost trial
    Brice Barefoot
    Duke Human Vaccine Institute, Duke University School of Medicine, DU Medical Center, 102 Research Drive, Durham, NC 27710, USA
    Vaccine 26:6108-18. 2008
    ..Comparative data such as those presented here are critical to efforts to generate protective vaccines for emerging infectious diseases as well as for biothreat agents...
  58. pmc Is developing an HIV-1 vaccine possible?
    Barton F Haynes
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA
    Curr Opin HIV AIDS 5:362-7. 2010
    ..This review discusses select recent data that suggest that indeed it is possible to make a clinically useful preventive vaccine for HIV-1 and outlines some of the remaining obstacles that stand in the way of success...
  59. pmc Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual
    Elin S Gray
    Duke Human Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710, USA
    J Virol 85:7719-29. 2011
    ..Our data validate the use of differential sorting to isolate a MAb targeting a specific epitope in the envelope glycoprotein and provided insights into the mechanisms of autologous neutralization escape...
  60. pmc High throughput functional analysis of HIV-1 env genes without cloning
    Jennifer L Kirchherr
    Duke Human Vaccine Institute and Center for HIV AIDS Vaccine Immunology, Department of Medicine, Duke University Medical Center, 112 RPIII, Research Drive, Box 3347, Durham, NC 27710, USA
    J Virol Methods 143:104-11. 2007
    ..The new pPCR method eliminates cloning, transformation, and plasmid DNA preparation steps in the generation of HIV-1 pseudovirions. This allows for quick analysis of multiple env genes from HIV-1 infected individuals...
  61. ncbi request reprint Centralized HIV-1 envelope immunogens and neutralizing antibodies
    Feng Gao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham NC 27710, USA
    Curr HIV Res 5:572-7. 2007
    ....
  62. ncbi request reprint Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF
    Hua Xin Liao
    Department of Medicine, Duke Human Vaccine Institute, Duke University Medical Center, Box 3258, Durham, NC 27710, USA
    Vaccine 20:2396-403. 2002
    ....
  63. pmc Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection
    Marc C Levesque
    Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America
    PLoS Med 6:e1000107. 2009
    ..While the effect of HIV-1 on depletion of gut CD4(+) T cells in acute HIV-1 infection is well described, we studied blood and tissue B cells soon after infection to determine the effect of early HIV-1 on these cells...
  64. pmc Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility
    Eden P Go
    Department of Chemistry, University of Kansas, Lawrence, Kansas 66045, USA
    J Proteome Res 7:1660-74. 2008
    ....
  65. ncbi request reprint Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies
    Mikyung Kim
    Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    AIDS Res Hum Retroviruses 21:58-67. 2005
    ..This ADAgp140 immunogen may be considered a starting point from which to engineer additional improvements for cross-reactive neutralizing antibody induction...
  66. pmc Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge
    Natalie J Thornburg
    Carolina Vaccine Institute, 9th Floor Burnett Womack, West Drive, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7292, USA
    Virology 362:441-52. 2007
    ..These results demonstrate that VRP may provide an effective alternative to vaccinia virus vaccines against poxvirus infection...